Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Aïda Benalycherif"'
Autor:
Roland Landman, Thomas-d'Aquin Toni, Coumba Toure-Kane, Daouda K. Minta, Gilles Peytavin, Frederic N. Ello, Eugène Messou, Almoustapha Issiaka Maiga, Jacques Zoungrana, Laure-Amelie de Monteynard, Mamadou Cisse, Ismael Diallo, Mouhamadou Baïla Diallo, Adrien Sawadogo, Xavier Anglaret, Lassana Sangaré, Amani Anzian, Malika Congo-Ouédraogo, Sophie Karcher, Jérome Le Carrou, Guillaume Bado, Serge Eholié, Marie-Laure Chaix, P M Girard, Audrey Gabassi, Delphine Gabillard, Aïda Benalycherif, Raoul Moh, Joseph Y Drabo, Moussa Seydi
Publikováno v:
The Lancet HIV
The Lancet HIV, 2019, 6 (11), pp.e750-e759. ⟨10.1016/s2352-3018(19)30228-0⟩
The Lancet HIV, 2019, 6 (11), pp.e750-e759. ⟨10.1016/s2352-3018(19)30228-0⟩
BACKGROUND: The decision about whether to switch to third-line antiretroviral therapy (ART) in patients with treatment failure on second-line therapy is difficult in settings with little access to genotypic resistance testing. In this study, we used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c801e7b870860a82abc58c17f7c4e6
http://hdl.handle.net/20.500.12278/38733
http://hdl.handle.net/20.500.12278/38733
Autor:
Valérie Boilet, Catherine Fagard, Cécile Rabian, Sybilla Peron, Caroline Roussillon, Françoise Couturier, Isabelle Cohen-Codar, Pierre-Marie Girard, Monique Termote, Eric Bellissant, Olivier Bouchaud, Karine Amat, Babacar Sylla, Aïda Benalycherif, O. Patey, Jean-Marie Poirier, Anne-Marie Taburet, Yazdan Yazdanpanah, Isabelle Poizot, Laetitia Moinot, Elisabeth Rouveix, Patrick Mercié, Eve Todesco, Amel Besseghir, Stéphane De Wit, Isabelle Pellegrin, Bruno Spire, Geneviève Chêne, Adélaïde Perrier, Laurence Morand-Joubert, Sandrine Couffin-Cadiergues, Roland Landman, Jean-Luc Meynard, S. Kolta, Vincent Bouteloup
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2018, 73 (6), pp.1672-1676. ⟨10.1093/jac/dky055⟩
Journal of Antimicrobial Chemotherapy, 2018, 73 (6), pp.1672-1676. ⟨10.1093/jac/dky055⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2018, 73 (6), pp.1672-1676. ⟨10.1093/jac/dky055⟩
Journal of Antimicrobial Chemotherapy, 2018, 73 (6), pp.1672-1676. ⟨10.1093/jac/dky055⟩
Background: Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. Objectives: To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab93fe6ca422ebbe14261f851b46f57
https://doi.org/10.1093/jac/dky055
https://doi.org/10.1093/jac/dky055
Autor:
Sinata Koulla-Shiro, Aïda Benalycherif, Gilles Peytavin, Ndeye Fatou Ngom Gueye, Sabrina Eymard-Duvernay, Pierre-Marie Girard, Charlotte Charpentier, Roland Landman, Vincent Le Moing, Eric Delaporte, Maguy Ngolle, Mahamadou-Baila Diallo, Papa Salif Sow
Publikováno v:
Antiviral Therapy. 19:51-59
Background The aim of the present study was to determine appropriate tenofovir-based regimens meriting evaluation in large-scale randomized trials among sub-Saharan African patients. Methods This was a randomized open-label 96-week prospective pilot
Autor:
Roland Landman, Claudine Duvivier, P. De Truchis, Aïda Benalycherif, Gilles Peytavin, Laurence Weiss, Jean L. Delassus, David Zucman, Diane Descamps, L. Tegna
Publikováno v:
Scandinavian Journal of Infectious Diseases. 45:407-410
The efficacy and safety of switching to a combined regimen containing darunavir/ritonavir (DRV/r) was investigated in a retrospective study.Sixty-six experienced patients receiving once-daily DRV/r (900/100 mg) in various regimens were included (medi
Autor:
M B Koita Fall, N F Ngom Gueye, Mboup S, Roland Landman, Halimatou Diop, M Poupard, Eric Delaporte, A. Trylesinski, M. Diallo, Ndella Diakhaté, P.S. Sow, Aïda Benalycherif, B Ndiaye, P M Girard, C. Touré Kane
Publikováno v:
Journal of the International Association of Physicians in AIDS Care. 8:379-384
We report the results of a pilot open-label trial of a tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) combination conducted in Dakar, Senegal. Forty HIV-1-infected patients, naive of antiretroviral treatment and without active opportunistic dise
Autor:
A. Benalycherif, Maryvonne Maynart, Mamadou-Baila Diallo, Sinata Koulla-Shiro, A. Ouattara, Charles Kouanfack, F. Ngom Gueye, Mireille Mpoudi Ngolle, S. Koulla-Shiro, Halimatou Diop, P.S. Sow, Aïda Benalycherif, Roland Landman, B. Ndiaye, R. Landman, Moussa Diallo, Ndeye Fatou Ngom Gueye, O. Elad, V. Le Moing, Maguy Ngolle, A. Sock, Claudine Ntsama Essomba, Papa-Salif Sow, Charlotte Charpentier, Sabrina Eymard-Duvernay, M B Koita Fall, E. Simen, P. M. Girard, C. Charpentier, C. Touré Kane, Gilles Peytavin, B. Ymele, Minh Patrick Lê, Avelin F. Aghokeng, S. Eymard-Duvernay, G. Peytavin, Sylvie Legac, Eric Delaporte, A. Thiam, Vincent Le Moing, Pierre-Marie Girard, E. Delaporte
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2015, 70 (5), pp.1517-1521. ⟨10.1093/jac/dku532⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2015, 70 (5), pp.1517-1521. ⟨10.1093/jac/dku532⟩
Objectives An open-label randomized trial (DAYANA) was conducted in sub-Saharan settings to evaluate four different regimens containing tenofovir disoproxil fumarate as first-line treatment for HIV infection. The objectives of the present substudy we
Autor:
Mboup S, M B Koita Fall, B Ndiaye, N F Ngom Gueye, P M Girard, C. Touré Kane, Roland Landman, Moussa Diallo, Y Bennai, Gilles Peytavin, P.S. Sow, Aïda Benalycherif
Publikováno v:
AIDS research and human retroviruses. 26(5)
The use of ritonavir as a protease inhibitor boost is rare in sub-Saharan Africa because a heat-stable formula is not available. We report the results of an open-label pilot trial with unboosted atazanavir in combination with lamivudine and didanosin
Autor:
Christine Katlama, Patrick Yeni, Aïda Benalycherif, A. Trylesinski, F. Brun Vezinet, Roland Landman, Diane Descamps, Pierre-Marie Girard, Philippe Flandre, M. Bentata, Christian Michelet, Michael D. Miller, Gilles Peytavin, B. Bonnet
Publikováno v:
HIV clinical trials. 6(6)
To assess the efficacy and safety of the triple NRTI combination of abacavir (ABC), lamivudine (3TC), and tenofovir (TDF) in a once-daily regimen.38 HIV-naive patients (pts) were treated in a prospective open-arm study over 48 weeks (W48). Virologica